Rhythm Pharmaceuticals EMANATE trial fails to meet primary endpoints

March 16, 2026 4:01 PM

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) announced that its Phase 3 EMANATE trial evaluating setmelanotide for rare genetic obesity conditions failed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found